Akebia Therapeutics (AKBA) Misses Q2 EPS by 3c

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $56.4 million versus the consensus estimate of $59.1 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22